RIPK1 kinase inhibition to preserve blood-brain barrier integrity in neuroinflammatory disease

Overview

Blood-brain barrier (BBB) breakdown is a hallmark of neurodegenerative and neuroinflammatory diseases such as Alzheimer's, ALS, and multiple sclerosis. This research program investigates the role of RIPK1 kinase activity in driving BBB dysfunction, with a specific focus on how RIPK1 activation in astrocytes transforms them into a reactive, neuroinflammatory state that compromises barrier integrity. The work has demonstrated that selective RIPK1 inhibition completely prevents BBB permeabilization and disease progression in the EAE (experimental autoimmune encephalomyelitis) model, even when administered after disease onset. Because clinical-stage RIPK1 inhibitors already exist, validating this mechanism could accelerate therapeutic development for multiple CNS disorders.

Technical specifications

Key research capabilities and findings:

• Validated EAE mouse model for studying BBB dysfunction and neuroinflammation
• Use of highly selective RIPK1 inhibitor GSK'547 to block BBB permeabilization, confirmed by Evans Blue dye leakage assays
• Flow cytometry-based assessment of CD4+ T cell infiltration into spinal cord and peripheral lymphoid organs
• Transcriptomic profiling of primary astrocytes and astrocytes isolated from EAE animals
• TRAP-seq using Aldh1L1-GFP-L10 mice for cell-type-specific enrichment of actively translated mRNAs in astrocytes
• Single-cell RNA-seq for detailed characterization of astrocyte reactive states
• Conditional genetic deletion of RIPK1 in astrocytes via Ripk1flox/flox crossed with GFAP-CreERT2 tamoxifen-inducible Cre mice
• Integration of RIPK1 biology expertise with astroglia biology expertise

Technology readiness level

The foundational observations have been published, including complete inhibition of EAE disease progression by GSK'547 after disease onset and demonstration that RIPK1 kinase activity drives inflammatory gene expression independently. Independent confirmation of BBB protection by the RIPK1 inhibitor RIPA-56 in EAE has been reported by another group. The program is currently at the preclinical validation stage, with active research aimed at defining the astrocyte-specific transcriptional signature of RIPK1 activation and the consequences of selective astrocyte RIPK1 deletion on BBB function and disease course. Findings are expected to inform the rational repurposing of clinical-stage RIPK1 inhibitors for CNS indications.